Market news
Detailed price information for Fulcrum Therapeutics Inc (FULC-Q) from The Globe and Mail including charting and trades.
Fulcrum Therapeutics, Inc. (NASDAQ:FULC) signed an all-stock merger agreement with Slate Medicines that would turn the public company into a migraine-focused biotechnology business. Slate is contributing its drug assets, while new investors are supplying $245 million. Legacy Slate holders would own approximately 55.9% of the combined company, PIPE investors 39.1%, and legacy Fulcrum holders 5%, […]
Detailed price information for Fulcrum Therapeutics Inc (FULC-Q) from The Globe and Mail including charting and trades.
After completion of the merger, the combined company will develop Slate’s migraine treatment pipeline.
By Karen Roman Fulcrum Therapeutics, Inc. (Nasdaq: FULC) said it is merging with Slate Medicines, Inc. to advance next-generation therapeutics to treat migraine and other headache disorders, with the combining company operating as Slate Medicines, Inc. and trading on Nasdaq under the ticker “SLTE.” Slate reported it secured an oversubscribed concurrent private placement of $245 […] The post Fulcrum Therapeutics & Slate Medicines Merge for Next-Generation Migraine Therapies appeared first on Exec
Fulcrum Therapeutics (NASDAQ:FULC) has entered into an all-stock merger agreement with privately held Slate Medicines, a migraine-focused biotechnology company, in a transaction expected to close in the fourth quarter of 2026, subject to stockholder approval and customary closing conditions. Alex S
Fulcrum Therapeutics (FULC) and Slate Medicines said Monday they have agreed to combine in an all-st
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
Detailed price information for Fulcrum Therapeutics Inc (FULC-Q) from The Globe and Mail including charting and trades.
The updated analyst framework for Fulcrum Therapeutics lifts the Fair Value estimate from US$5.43 to US$5.83 per share. This shift in price target sits against a backdrop of sharply changed Street commentary after the decision to discontinue pociredir, with more focus on cash, restructuring and the ongoing review of options than on late stage development potential. Read on to see how this evolving narrative could matter for your own view on Fulcrum Therapeutics and how to track the next set...
Detailed price information for Fulcrum Therapeutics Inc (FULC-Q) from The Globe and Mail including charting and trades.
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
This is the newest page. Registered accounts read further back.